Press Releases

Washington D.C., Feb. 18, 2025- The Global Alzheimer’s Platform Foundation ® (GAP) is gravely concerned over news of terminations of key leaders at the National Institute of Health and the Federal Drug Administration along with the firing of thousands of employees from the Department of Health and Human Services over the weekend. John Dwyer, the […]

Washington D.C., Feb. 18, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities […]

Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data  Washington D.C., Jan. 30, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for aging and longevity. Through a memorandum […]

Washington D.C., Jan. 27, 2025– Global Alzheimer’s Platform Foundation® (GAP) applauds the U.S. Food and Drug Administration (FDA)’s approval of IV maintenance dosing for the treatment LEQEMBI®. With this approval, after a patient completes 18 months of once every two weeks initiation phase, a transition to the maintenance dosing regimen of once every four weeks […]

Tampa, Fla. Jan. 24, 2025—Axiom Brain Health (Axiom) and the Global Alzheimer’s Platform Foundation® (GAP) celebrated the next chapter in neurodegenerative research at the launch of the newly renovated site on Thursday, January 23. The expansion of the research facility accommodates the growing need for more research of Alzheimer’s, Multiple Sclerosis, Parkinson’s, and other life-threatening […]

Washington D.C., Jan. 23, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002 study. This first-time collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images […]

Washington D.C., Dec. 9, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This collaboration will enrich the unique, observational platform study that compares blood-based and digital biomarkers across a broad range of races and ethnicities that may help predict and diagnose Alzheimer’s […]

Washington D.C., Nov. 26, 2024- The Centers for Medicare & Medicaid Services (CMS) released the Clinical Laboratory Fee Schedule (CLFS) 2025 Final Rate Determinations yesterday, unveiling that clinically critical codes for the reimbursement of Alzheimer neurological biomarker blood tests have been referred to the process known as “gapfill.” Earlier this year, the preliminary recommendation for […]

Washington D.C., Nov. 18, 2024- Global Alzheimer’s Platform Foundation® (GAP) is welcoming a new clinical research site into its international network of best-in-class research sites, Jacksonville Center for Clinical Research of Jacksonville, Florida. Jacksonville Center for Clinical Research (JCCR) is a premier clinical research site, having conducted more than 1,000 clinical trials over 25 years with […]

Washington D.C., Nov. 4, 2024 – Global Alzheimer’s Platform Foundation® (GAP) applauds Eisai and Biogen on the completion of the rolling submission of the application to the U.S. Food and Drug Administration (FDA) for the subcutaneous maintenance dosing of Leqembi. If approved, this autoinjector could greatly improve the patient experience, reducing the need for biweekly one-hour visits […]

Global Alzheimer’s Platform Foundation Announces Strategic Partnerships for the Transformative Bio-Hermes-002 Study   Washington D.C., Oct. 28, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome the initial strategic partners in the Bio-Hermes-002 study. These collaborations will enhance the unique, observational platform study that compares blood-based and digital biomarkers across a broad range […]

October 10, 2024 The state of Florida just stood up to the assault of Hurricane Helene, followed by Milton, a ferocious one-two punch in the 2024 hurricane season.  The Global Alzheimer’s Platform Foundation® (GAP) is relieved and very grateful that our Florida GAP-Net sites, our Florida GAP partners and our own FL-based GAP team members, […]

Partnership to Cultivate Best-In Class Clinical Research Services for Alzheimer’s disease and related dementias Washington D.C. – Sept 19, 2024 – Global Alzheimer’s Platform Foundation® (GAP) and the University of Nevada, Las Vegas (UNLV), announced a memorandum of understanding (MOU) regarding a collaboration to accelerate research for neurodegenerative diseases. This includes establishing a state-of-the-art imaging and emerging technology […]

 Non-profit expands research network to Southeast Texas to improve access to research opportunities   Washington D.C., Aug. 8, 2024-?Global Alzheimer’s Platform Foundation® (GAP) is welcoming a new clinical research site into its global network of best-in-class research sites, Gadolin Research of Beaumont, Texas.  Gadolin Research is dedicated to advancing medical knowledge and improving healthcare outcomes through innovative […]

Partnership to Cultivate Best-In Class Clinical Research Services for Alzheimer’s disease and related dementias Washington D.C. – July 12, 2024 – Today, Global Alzheimer’s Platform Foundation® (GAP) and the University of Nevada, Las Vegas (UNLV), announced a memorandum of understanding (MOU) regarding a collaboration to accelerate research for neurodegenerative diseases. This includes establishing a state-of-the-art […]

Collaboration with Innovate UK Yields New Partners for Alzheimer’s Study Washington D.C., July 10, 2024- With groundbreaking creativity and breathtaking speed, this phase 3 competition, funded by Innovate UK, the UK’s innovation agency, is supporting organizations committed to improving dementia research using blood-based and digital biomarkers.   This competition received 14 proposals within one week, from […]

Washington D.C., July 8, 2024- Global Alzheimer’s Platform Foundation® (GAP) announced the appointment of Leigh Zisko, MPH as Chief Impact Officer and Tamiko MaGee-Rodgers, PhD, CCRP as the Director of Recruitment and Strategic Initiatives. In newly created global leadership roles, each will meaningfully contribute new perspectives and experience to GAP’s work in innovating clinical trial […]

Washington D.C., July 2, 2024- Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer applauds the U.S. Food and Drug Administration (FDA) for its decision granting full traditional approval of Eli Lilly and Company’s Kisunla™ (donanemab), a disease-modifying Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease (AD).  “Today, the FDA grants full approval for donanemab, […]

Washington D.C., July 1, 2024- The Food and Drug Administration (FDA) unveiled a draft guidance document, “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies,” which is open for public comment. This draft guidance points to improving participation from people who are traditionally underrepresented in clinical trials. John Dwyer, President […]

Global non-profit expands research network to the greater New Orleans areato improve access to research opportunities Washington D.C., June. 17, 2024- Global Alzheimer’s Platform Foundation® (GAP) is welcoming its first clinical research site from Louisiana into its network, Tandem Clinical Research of greater New Orleans. Tandem Clinical Research, a Prolerity Clinical Research Company site, advances […]

Washington D.C., June. 14, 2024- Global Alzheimer’s Platform Foundation® (GAP) proudly collaborated with The Global CEO Initiative on Alzheimer’s Disease (CEOi) to release the peer-reviewed publication of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease,” in Nature Reviews Neurology. Alzheimer’s blood tests have the […]

Washington D.C., June.10, 2024- Global Alzheimer’s Platform Foundation® (GAP) –applauds the U.S. Food and Drug Administration (FDA)’s acceptance of Eisai’s application for the subcutaneous maintenance dosing of Leqembi. With an action date set for January 25, 2025, this autoinjector will be used for weekly maintenance dosing and stands to reduce the burden on patients who are eligible to receive this disease-modifying therapy, as it can be used […]

Support from Scottish Parliament Underscores Its Significance Washington D.C., May 30, 2024-  The Global Alzheimer’s Platform Foundation® (GAP)  and the Scottish Funding Council’s Brain Health ARC have announced swift progress in the next steps of the Bio-Hermes Biomarker Data Challenge 2024, the research competition using the most comprehensive set of dementia biomarker data from ground-breaking […]

Washington D.C., Mar. 25, 2024- The Global Alzheimer’s Platform Foundation® (GAP) – which is focused on global game-changing dementia research – has chosen Scotland to host the Bio-Hermes Biomarker Data Challenge 2024, a research competition using the most comprehensive set of dementia biomarker data from ground-breaking early blood testing studies for Alzheimer’s disease. Researchers at […]